Source comparison
Comparison Table: Top Research Peptides for Concussion Recovery
This table compares the three most-studied peptides for post-concussion intervention based on mechanism, evidence quality, and practical application in research settings. BPC-157 Stabilizes blood-brain barrier, reduces neuroinflammation, upregulates VEGF for a
This comparison does not assign a generated winner or score.
- This table compares the three most-studied peptides for post-concussion intervention based on mechanism, evidence quality, and practical application in research settings.
- BPC-157
- Stabilizes blood-brain barrier, reduces neuroinflammation, upregulates VEGF for angiogenesis
- Preclinical only (rat TBI models). No human RCTs
- 200–500 μg daily subcutaneous
- Subcutaneous injection
- Acute (0–72 hours)
- Best acute-phase option for reducing secondary injury cascade
- Cerebrolysin
- Increases BDNF, promotes synaptic plasticity, mimics NGF and GDNF activity
- Human RCTs in moderate-severe TBI. Meta-analysis shows modest cognitive benefit
- 30–50 mL IV daily for 10–21 days
- Intravenous infusion
- Subacute (3–30 days)
- Most robust human evidence but requires clinical administration
- Semax
- Reduces glutamate excitotoxicity, upregulates BDNF, protects mitochondria via PI3K/Akt pathway
- Preclinical + small human studies in stroke. Limited TBI-specific data
- 300–600 μg intranasal or 0.1% solution
- Intranasal spray
- Acute to subacute (0–14 days)
- Most practical for early intervention but evidence base is narrower